Hyperfine, Inc. announced that its Swoop® portable magnetic resonance imaging system began clinical use at the All India Institute of Medical Sciences (AIIMS) in New Delhi on April 29 2026, marking the first bedside MRI deployment in India.
AIIMS is the country’s premier autonomous public medical university and a national referral center for tertiary care, medical education, and biomedical research. The Swoop system’s ultra‑low‑field technology eliminates the need for specialized shielding or cryogenic cooling, allowing the scanner to be brought directly to the patient’s bedside. The deployment follows Hyperfine’s regulatory approval from the Central Drugs Standard Control Organization (CDSCO) in December 2025 and the exclusive distribution agreement with Radiosurgery Global, Ltd. in India.
The Swoop platform offers a cost‑effective alternative to conventional 1.5‑3 T scanners, improving diagnostic speed and reducing patient transport risk. By enabling high‑quality brain imaging at the point of care, the system addresses a critical gap in India’s healthcare infrastructure, where there are only about 3.5 MRI scanners per million people compared with 38 per million in the United States.
Strategically, the AIIMS milestone expands Hyperfine’s footprint into the world’s largest healthcare market and supports its multi‑pronged growth strategy of targeting neurology offices and international markets to diversify revenue streams and reduce customer concentration risk. The successful launch in India is a tangible indicator of Hyperfine’s progress toward scaling its portable MRI solution worldwide and is expected to open additional opportunities across South Asia and other emerging markets.
The event underscores the growing acceptance of Hyperfine’s technology outside the United States and highlights the company’s ability to deliver a portable, low‑field MRI that meets the needs of hospitals with limited traditional MRI infrastructure. While the article does not include financial figures, the deployment signals a significant operational achievement that could influence future revenue growth and market penetration in India and beyond.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.